RxDoctor Payments DataLook up a doctor →

Steven Wallentine, MD

Hematology & Oncology · Provo, UTNPI 1790736122

Payments from drug & device makers

$7,050in general payments, 2019–2025

Across 389 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$580
  • Novartis$531
  • Amgen$467
  • AstraZeneca$435
  • E.r. Squibb & Sons, L.L.C.$384
  • Merck$373
  • plus $4K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer46$580
Novartis29$531
Amgen27$467
AstraZeneca(2 entities)24$435
E.r. Squibb & Sons, L.L.C.15$384
Merck20$373
Johnson & Johnson(2 entities)16$331
Astellas Pharma US Inc15$301
Sanofi12$268
GSK14$251
EMD Serono, Inc.13$239
Daiichi Sankyo Inc.10$231
Genentech USA, Inc.9$207
Seagen Inc.11$204
Array Biopharma Inc9$146
Bristol Myers Squibb7$138
Eisai Inc.8$136
Lilly USA, LLC9$124
Puma Biotechnology, Inc.6$102
AbbVie4$102
Gilead(2 entities)6$98
Bayer5$92
Incyte Corporation5$84
AVEO Pharmaceuticals, Inc.4$78
Exelixis Inc.4$73
Karyopharm Therapeutics Inc.3$65
Regeneron Healthcare Solutions, Inc.2$51
Helsinn Therapeutics (U.S.), Inc.3$50
Agios Pharmaceuticals, Inc.3$49
Jazz Pharmaceuticals Inc.3$48
Tesaro, Inc.3$47
Genmab U.S., Inc.2$43
Geron Corporation2$42
Dendreon Pharmaceuticals LLC2$41
Secura Bio, Inc.3$41
Pharmacyclics LLC, An Abbvie Company2$40
Coherus Oncology, Inc.2$39
Sumitomo Pharma America, Inc.2$38
Servier Pharmaceuticals LLC2$31
Sobi, Inc1$29
Clovis Oncology, Inc.3$29
Histosonics, Inc.1$25
Foundation Medicine, Inc.2$23
Pharmaand GmbH1$23
Deciphera Pharmaceuticals Inc.1$21
Boehringer Ingelheim1$21
Heron Therapeutics, Inc.1$20
Ipsen Biopharmaceuticals, Inc1$19
Fennec Pharmaceuticals, Inc.1$19
CTI Biopharma Corp.1$19
Springworks Therapeutics, Inc.1$19
Rigel Pharmaceuticals, Inc.1$19
Pharming Healthcare, Inc.1$18
Azurity Pharmaceuticals, Inc.1$17
Kyowa Kirin, Inc.1$17
Pharmaessentia USA Corporation1$16
Acrotech Biopharma Inc.1$16
Mylan Institutional Inc.1$15
Lexicon Pharmaceuticals, Inc.1$15
Akcea Therapeutics, Inc.1$14

How this compares

$7,050 in reported general payments places this provider in the 40th percentile of 77 hematology & oncology providers in Utah.

See all hematology & oncology providers in Utah →

Medicare billing

Part B allowed, 2024
$3,718,845
Medicare patients
1,292
Services billed
195,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Provo

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →